TAGNOLOGIES
DEAD

Serial Number

78501419

Owner

IBA GMBH

Attorney

Helen Hill Minsker

Filing Date

Oct 18, 2004

Add to watchlist:

No watchlists yet
View on USPTO

TAGNOLOGIES Trademark

Serial Number: 78501419

TAGNOLOGIES is a trademark filed by IBA GMBH on October 18, 2004. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

IBA GMBH (10 trademarks)

RUDOLF-WISSELL-STRABE 28
37070 GOTTINGEN , DE

Entity Type: 16

Trademark Details

Filing Date

October 18, 2004

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for the treatment of immunological diseases, auto-immune diseases, viral diseases and cancer, and veterinary preparations, in particular nucleic acids, peptides and proteins including fusion proteins, viruses or viroids, cells, in particular body cells and cells of the immune system of mammals including human cells, furthermore chemically and/or by means of gene technology produced combination products of proteins and/or peptides and other proteins or peptides or nucleic acids or viruses or viroids or cells, diagnostics for medical purposes as well as antisera and vaccines

Chemicals used in industry and science, in particular proteins including fusion proteins, in particular streptavidin and streptavidin muteins, antibodies, kinases, phosphatases, proteases, G proteins and G protein coupled receptors, peptides, in particular affinity peptides, peptides mediating cell membrane permeation as well as peptides mediating cell and tissue specifity, nucleic acids, in particular nucleic acids encoding the aforementioned proteins and peptides, vectors, in particular expression vectors as well as chemically synthesized oligonucleotides and nucleic acids, especially DNA, RNA, LNA, namely locked nucleic acid and PNA, namely peptide nucleic acid, oligonucleotides, oligonucleotides optionally furnished with an attached dye, viruses or viroids, cells, in particular body cells and cells of the immune system of mammals including human cells, combination products of proteins and/or peptides and other proteins or peptides or nucleic acids or viruses or viroids or cells, kits for analysis comprised of resin for chromatographic separation of proteins and polypeptides and buffers for purification of proteins, kits for analysis comprised of a purification column packed with resin for chromatographic separation of proteins and polypeptides, and buffers for purification of proteins and polypeptides, kits for analysis comprised of a purification column packed with resin for chromatographic separation of protein and polypeptides, buffers for purification of proteins and polypeptides, and reagent for Western Blot detection of proteins, kits for analysis comprised of a purification column packed with resin for chromatographic separation of proteins and polypeptides, buffers for purification of proteins and polypeptides, reagent for Western Blot detection of proteins, an expression vector for recombinant production of proteins and polypeptides and reagent for inducing recombinant gene expression , and test agents, produced chemically and/or by means of gene technology for use in industry and science for purification and/or labeling and/or funcitionalization and/or detection and/or immobilization of nucleic acids, peptides and proteins including fusion proteins, viruses, viroids and/or cells, in particular of body cells and cells of the immune system of mammals including human cells, diagnostics, except for medical purposes

Research in science and industry in the areas of biochemistry, diagnostics and pharmaceuticals, services of an analytical, biochemical or pharmaceutical laboratory, in particular synthesis and purification of peptides and proteins, purification of viruses and viroids, cultivation and purification of cells, in particular of body cells and cells of the immune system of mammals including human cells, synthesis of nucleic acids and oligonucleotides, synthesis of vectors, in particular of expression vectors, preparation of combination products of proteins and/or peptides and other proteins or peptides or nucleic acids or viruses or viroids or cells by chemical means and/or means of gene technology, synthesis of active pharmaceutical agents as well as isolation of antisera and vaccines

Filing History

ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT
Jan 23, 2007 MAB1
ABANDONMENT - EXPRESS MAILED
Jan 23, 2007 ABN1
TEAS EXPRESS ABANDONMENT RECEIVED
Jan 23, 2007 EXAR
ASSIGNED TO EXAMINER
Oct 6, 2006 DOCK
INQUIRY TO SUSPENSION E-MAILED
Jul 23, 2006 GNSI
SUSPENSION INQUIRY WRITTEN
Jul 23, 2006 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jun 16, 2006 RCCK
LETTER OF SUSPENSION E-MAILED
Dec 14, 2005 GNSL
SUSPENSION LETTER WRITTEN
Dec 14, 2005 CNSL
AMENDMENT FROM APPLICANT ENTERED
Dec 5, 2005 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 17, 2005 CRFA
PAPER RECEIVED
Nov 17, 2005 MAIL
NON-FINAL ACTION E-MAILED
May 25, 2005 GNRT
NON-FINAL ACTION WRITTEN
May 25, 2005 CNRT
ASSIGNED TO EXAMINER
May 19, 2005 DOCK
NEW APPLICATION ENTERED
Oct 26, 2004 NWAP